Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia

Melita Kenealy, Mark Hertzberg, Warwick Benson, Kerry Taylor, Ilona Cunningham, Will Stevenson, Devendra Hiwase, Richard Eek, Daniela Zantomio, Steve Jong, Meaghan Wall, Piers Blombery, Tracey Gerber, Marlyse Debrincat, Diana Zannino, and John F. Seymour

Disclosures: MK, DH, JFS received research funding from Celgene MK and JFS are advisory board members for Celgene JFS is a member of speakers bureau for Celgene MH is an advisory board member for Takeda, Roche, MSD, Gilead, Janssen WS receives honoraria from Amgen and Novartis The remaining authors declare no conflict of interest; IC, KT, DZant, MW, MD, RE, SJ, TG, DZann, PB, WB.

Contributions: MK and JFS contributed to the concept and design of the study; MK, JFS, MH, WB, KT, IC, WS, DH, RE, DZant recruited patients to the study, MK, JFS, TG, MD, DZann contributed to the acquisition and analysis of the data; MW and PB performed and analyzed the NGS and SNP-arrays, MK and SJ wrote the manuscript; all authors critically reviewed the manuscript and approved the final version.